DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 6,410,224
|Title:||Ribozyme treatment of diseases or conditions related to levels of NF-.kappa.B|
|Abstract:||Enzymatic RNA molecules which cleave rel A mRNA.|
|Inventor(s):||Stinchcomb; Dan T. (Boulder, CO), Draper; Kenneth G. (Boulder, CO), McSwiggen; James (Boulder, CO)|
|Assignee:||Ribozyme Pharmaceuticals, Inc. (Boulder, CO)|
|Patent Claims:||1. A method for specifically cleaving RNA encoding a Rel-A subunit of NF-k B protein using an enzymatic RNA molecule, comprising the step of contacting said RNA with said
enzymatic RNA molecule under conditions suitable for said cleaving.
2. The method of claim 1, wherein said enzymatic RNA molecule is in a motif selected from the group consisting of Hammerhead, Hairpin, Hepatitis Delta Virus, Group I Intron, RNAse P RNA and VSRNA.
3. A method of claim 1, wherein said enzymatic RNA molecule comprises between 12 and 100 nucleotides complementary to said RNA encoding the Rel-A subunit of the NF-kB protein.
4. A method of claim 1, wherein said enzymatic RNA molecule comprises between 14 and 24 nucleotides complementary to said RNA encoding the Rel-A subunit of the NF-kB protein.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||Ribozyme Pharmaceuticals, Inc. (Boulder, CO)||2012-12-07||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||Ribozyme Pharmaceuticals, Inc. (Boulder, CO)||2012-12-07||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||Ribozyme Pharmaceuticals, Inc. (Boulder, CO)||2012-12-07||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|United States of America||2001006801||Start Trial|
|United States of America||2002013458||Start Trial|
|United States of America||2002082225||Start Trial|
|United States of America||2002192685||Start Trial|
|United States of America||2002193579||Start Trial|
|United States of America||2002197684||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.